Dongkook receives reimb for s-amlodipine triple-drug combo
By Lee, Tak-Sun | translator Alice Kang
24.10.22 05:14:57
가나다라
0
Price is the same as Sevikar HCT... May be useful as a second-line treatment
▲Olmevikar, a combination of s-amlodipine and olmesartan currently sold by Dongguk. The company will sell Olmevikar HCT from November, which contains Olmevikar and hydrochlorothiazide
Dongkook Pharmaceutical has succeeded in becoming the first Korean company to receive reimbursement for a three-drug combination drug for hypertension that combines the CCB ‘s-amlodipine,’ ARB ‘olmesartan’ and diuretic ‘hydrochlorothiazide’.The combination therapy is expected to be useful for patients whose blood pressure is not adequately controlled with the company's combination product, s-amlodipine+olmesartan. Only Dongkook Pharmaceutical and Ahngook Pharm owns an s-amlodipine+olmesartan combination drug.
According to industry sources on the 21st, Dongkook Pharmaceutical will start selling three types of Olmevikar HCT Tab beginning November, 1 with reimbursement.
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)